Key drugs Repatha, Aimovig flail as cheap copies eat into Amgen sales

As copycats eat into Amgen’s older products, the Big Biotech is looking to its newer launches to stem the tide. But some of them are not getting it done.

J.P. Morgan analyst Cory Kasimov name-dropped CGRP migraine med Aimovig and PCSK9 contender Repatha in particular in a note to clients Tuesday, calling their Q1 sales haul “somewhat discouraging.”